From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Cardio protection in patients at high risk of anthracycline induced cardiotoxicity

Last Updated: Monday, August 28, 2023

Anthracyclines are frequently used with curative intent in breast cancer, and other solid tumors but there’s concern about the potential of anthracycline-related myocardial injury and development of left ventricular dysfunction and heart failure. This review shares evidence for cardioprotective strategies to reduce anthracycline cardiotoxicity in high-risk patients. 

JACC Cardio Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement